Wang et al., 2013 - Google Patents
Epigenetic mechanisms in Alzheimer's disease: implications for pathogenesis and therapyWang et al., 2013
- Document ID
- 9879052611371198136
- Author
- Wang J
- Yu J
- Tan M
- Jiang T
- Tan L
- Publication year
- Publication venue
- Ageing research reviews
External Links
Snippet
The vast majority of Alzheimer's disease (AD) are late-onset forms (LOAD) likely due to the interplay of environmental influences and individual genetic susceptibility. Epigenetic mechanisms, including DNA methylation, histone modifications and non-coding RNAs …
- 206010001897 Alzheimer's disease 0 title abstract description 219
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Epigenetic mechanisms in Alzheimer's disease: implications for pathogenesis and therapy | |
| Qazi et al. | Epigenetics in Alzheimer’s disease: perspective of DNA methylation | |
| Nunomura et al. | RNA and oxidative stress in Alzheimer’s disease: focus on microRNAs | |
| Johnson et al. | The role of DNA methylation in aging, rejuvenation, and age-related disease | |
| Cheng et al. | 5-Hydroxymethylcytosine: A new player in brain disorders? | |
| Szyf | Prospects for the development of epigenetic drugs for CNS conditions | |
| Handy et al. | Epigenetic modifications: basic mechanisms and role in cardiovascular disease | |
| Adwan et al. | Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease | |
| Cacabelos et al. | Epigenetics of aging and Alzheimer’s disease: Implications for pharmacogenomics and drug response | |
| Mastroeni et al. | Epigenetic mechanisms in Alzheimer's disease | |
| Day et al. | Epigenetic treatments for cognitive impairments | |
| Narayan et al. | Pharmacology of epigenetics in brain disorders | |
| Pan et al. | Inhibition of DNA methyltransferases blocks mutant huntingtin-induced neurotoxicity | |
| Waseem Bihaqi et al. | Do epigenetic pathways initiate late onset Alzheimer disease (LOAD): towards a new paradigm | |
| Bekdash | Choline, the brain and neurodegeneration: insights from epigenetics | |
| Jimenez-Pacheco et al. | Epigenetic mechanisms of gene regulation in amyotrophic lateral sclerosis | |
| Cacabelos et al. | Epigenomics of Alzheimer's disease | |
| Lardenoije et al. | Neuroepigenetics of aging and age-related neurodegenerative disorders | |
| Yu et al. | Epigenetic modulation on tau phosphorylation in Alzheimer’s disease | |
| Cuadrado-Tejedor et al. | Epigenetic drugs in Alzheimer’s disease | |
| Gürel et al. | The clues in solving the mystery of major psychosis: the epigenetic basis of schizophrenia and bipolar disorder | |
| Song et al. | Epigenetic modification in Parkinson’s disease | |
| Mir et al. | Neuroepigenetics of ageing and neurodegeneration-associated dementia: an updated review | |
| Daniilidou et al. | Epigenetic mechanisms in Alzheimer's disease | |
| Kumar et al. | Epigenetics mechanisms in ischemic stroke: a promising avenue? |